貝萊德世界健康科學基金Hedged A2 澳幣
19.67澳幣0.34(1.7%)
2021/02/26更新
以盡量提高總回報為目標。基金將不少於70%的資產投資於全球各地主要從事保健、製藥、醫學科技 及生物科技供應及開發業務的公司之股票。 本基金亦可投資於其他新興市場（例如巴西、南非及南韓）。
| 大型 | |||
|---|---|---|---|
| 中型 | |||
| 小型 | |||
| 價值型 | 均衡型 | 增長型 |
Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.